A Review on Advances in Personalized Medicine: from Genomics to Clinical Applications

Authors

  • Surya Prakash DV Department of Biotechnology, Meerut Institute of Engineering and Technology (MIET), Meerut-250005, UP, India.
  • Akshita Vishnoi
  • Himani Sharawat

DOI:

https://doi.org/10.37591/rrjodfdp.v10i2.1343

Keywords:

Precision, Health, Genomics, Biomarker, Diagnostic.

Abstract

Personalised medicine, also known as precision medicine, is a revolutionary approach to healthcare that customises medical interventions and treatments for individual patients according to their distinct genetic, environmental, and lifestyle properties. The basic pillar of personalised medicine is genomics, and the area has seen an explosion of genetic information with the advent of high-throughput sequencing tools. Genomic data now provide unprecedented insights into the underlying genetic variations, mutations, and genetic predispositions that underpin disease. These advancements have resulted in the identification of multiple disease-associated genes and biomarkers, allowing for the evaluation of risk, diagnosis at an early stage, and targeted therapy for a variety of ailments such as cancer, cardiovascular disease, and rare genetic disorders.The invention of pharmacogenomics, which uses a patient's genetic composition to predict how they will react to a particular medication, is one of the most amazing advances in personalised medicine. This customised strategy aids in preventing negative drug reactions and improving the results of treatment. Moreover, a thorough understanding of disease mechanisms has been made possible by the integration of omics data (genomics, transcriptomics, proteome, and metabolomics), opening the door for the creation of novel therapeutic approaches.Advances in molecular diagnostics, such as liquid biopsies, have enabled non-invasive monitoring of disease progression and therapy response.

References

Shabaruddin, F. H., Fleeman, N. D., & Payne, K. (2015). Economic evaluations of personalized medicine: existing challenges and current developments. Pharmacogenomics and Personalized Medicine, 115-126.

Graig LA, Phillips JK, Moses HL, editors. Biomarker tests for molecularly targeted therapies: key to unlocking precision medicine. Washington, DC: National Academies Press; 2016.

Gupta S, Jhawat V. Quality by design (QbD) approach of pharmacogenomics in drug designing and formulation development for optimization of drug delivery systems. J Control Release. 2017;245:15–26.

Hewitt, R. E. (2011). Biobanking: the foundation of personalized medicine. Current opinion in oncology, 23(1), 112-119.

Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., Kloczkowski, A. (2022). Innovations in genomics and big data analytics for personalized medicine and health care: A review. International journal of molecular Sciences, 23(9), 4645.

Ginsberg GS, Willard HF, editors. Genomic and Personalized Medicine. 2nd. London: Academic Press; 2013.

Alonso, S. G., de la Torre Díez, I., &Zapiraín, B. G. (2019). Predictive, personalized, preventive and participatory (4P) medicine applied to telemedicine and eHealth in the literature. Journal of medical systems, 43, 1-10.

Maayan, A., and Jenkins, S. L. Systems pharmacology meets predictive, preventive, personalized and participatory medicine. Pharmacogenomics 14(2):119–122, 2013.

Whirl‐Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F.,Klein, T.E. (2012). Pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 92(4), 414-417.

Ehmann, F., Caneva, L., Prasad, K., Paulmichl, M., Maliepaard, M., Llerena, A., Papaluca-Amati, M. (2015). Pharmacogenomic information in drug labels: European Medicines Agency perspective. The pharmacogenomics journal, 15(3), 201-210.

Woodcock, J. (2007). The prospects for “personalized medicine” in drug development and drug therapy. Clinical Pharmacology & Therapeutics, 81(2), 164-169.

Guglielmo, A., Staropoli, N., Giancotti, M., & Mauro, M. (2018). Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations. Cost Effectiveness and Resource Allocation, 16(1), 1-14.

Hamburg, M. A., Collins, F. S. (2010). The path to personalized medicine. New England Journal of Medicine, 363(4), 301-304.

Collins FS, Morgan M, Patrinos A (2003). The Human Genome Project: lessons from large-scale biology. Science, 300, 286-290.

Hindorff LA, Bonham VL, Brody LC, et al.(2018). Prioritizing diversity in human genomics research. Nat Rev Genet. 19, 175-185. 16.Broeders M, Herrero-Hernandez P, Ernst MPT, van der Ploeg AT, Pijnappel WWMP. Sharpening the molecular scissors: advances in gene-editing technology. iScience. 23:100789-100789.

Downloads

Published

2023-10-30

Issue

Vol. 10 No. 2 (2023)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.